Introduction
============

Breast cancer is one of the most frequently occurring cancer and cancer-related deaths are highly prevalent worldwide, which has become a major public health challenge \[[@B1]\]. The mechanism of developing breast cancer is still unclear. It has been widely accepted that exposure to circulating estrogen may be important in the development of breast cancer. Since estrogen biosynthesis and metabolism consist of many translation and transcription steps, the genes involved in these processes may contribute to the level of estrogen and thereby influence the susceptibility to breast cancer. Among the genes identified, *BRCA1* and *BRCA2* mutations have been reported to be associated with a dominantly inherited increased risk of the disease. However, they only account for about 5% of breast cancer occurrences \[[@B2]\]. This fact leaves the possibility that low-penetrance genetic factors are likely to explain most of disease cases.

Catechol-O-methyltransferase (*COMT*) is an important phase II enzyme involved in the conjugation and inactivation of catechol estrogens \[[@B3]\]. *COMT* is expressed at high levels in a variety of human tissues including liver, kidney, breast, and red blood cells \[[@B4]\]. The *COMT* gene is located on chromosome 22q11 \[[@B5]\]. A G to A transition in the *COMT* gene results in valine to methionine amino acid change in codon 108/158 in the cytosolic/membrane-bound form of the protein. This amino acid change is believed to result in a 3--4-fold decrease in enzymatic activity \[[@B6],[@B7]\]. Since the variant form (Met) has been associated with decreased activity of the *COMT* compared with the wildtype (Val), these two forms are represented as *COMT*-L allele and *COMT*-H allele, respectively. It has been hypothesized that the individuals who inherit the low activity *COMT*-L gene may be at increased risk for breast cancer because of an increased accumulation of the catechol estrogen intermediates \[[@B8]-[@B11]\].

The role of COMT Val158Met polymorphism in the development of breast cancer has been investigated in the past decade, with conflicting results. Several studies have previously suggested an association between the COMT Val158Met polymorphism and an increased risk of breast caner \[[@B12]-[@B14]\]. However, other studies have failed to confirm such an association \[[@B15],[@B16]\]. Moreover, two meta-analyses investigating the same hypothesis \[[@B17],[@B18]\], quite similar in methods and performed almost at the same time, yielded different conclusions. The exact relationship between genetic polymorphisms of COMT Val158Met and susceptibility to breast cancer has not been entirely established. To clarify the effect of COMT Val158Met on the risk of breast cancer, our study undertakes a meta-analysis of all published case--control observational studies.

Materials and methods
=====================

Search strategy
---------------

Electronic databases PubMed ( <http://www.ncbi.nlm.nih.gov/pubmed/>), Embase ( <http://www.embase.com/>) and Cochrane Library ( <http://www.thecochranelibrary.com/view/0/index.html>) were used to search for all genetic association studies evaluating the *COMT* Val158Met polymorphism and breast cancer risk up to February 2012, the search strategy was based on combinations of "Breast cancer", "Catechol-O-methyltransferase", "*COMT*", "polymorphism", and "mutation". No language or country restrictions were applied. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. Review articles and bibliographies of other relevant studies identified were searched by hand to find additional eligible studies. When multiple publications reported on the same or overlapping data, we chose the most recent or largest population. When a study reported the results on different subpopulations, we treated it as separate studies in the meta-analysis.

Selection criteria
------------------

Studies included in our meta-analysis had to meet the following inclusion criteria: (1) evaluate the association between *COMT* Val108/158Met polymorphism and breast cancer risk; (2) case--control design; (3) sufficient data for estimating an odds ratio (OR) with 95% confidence interval (CI); and (4) studies with full text articles. Studies were excluded if one of the following existed: (1) no control population; and (2) duplicate of previous publication.

Data extraction
---------------

Information was carefully extracted from all eligible publications by two investigators (Xue Qin and Qiliu Peng) independently according to the inclusion criteria listed above. For conflicting evaluation, an agreement was reached following discussion during a consensus meeting with a third reviewer (Aiping Qin). For each study, the following information were collected: First author's name, year of publication, country, ethnicity of the studied population, total numbers of cases and controls, breast cancer diagnosis criteria, matching criteria, genotyping method, menopausal status, sources of the control population, quality control of genotyping and *P* value for control population in Hardy--Weinberg equilibrium (HWE). We did not define any minimum number of patients to include in our meta-analysis.

Statistical analysis
--------------------

Crude odds ratios (ORs) together with their corresponding 95% CIs were used to assess the strength of association between the *COMT* Val158Met polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (LL vs. HH, HL vs. HH, and LL vs. HL), dominant model (LL+ HL vs. HH), and recessive model (LL vs. HL+HH), respectively. Departure from the Hardy--Weinberg equilibrium for the control group in each study was assessed using a web-based program ( <http://ihg2.helmholtz-muenchen.de/cgibin/hw/hwa1.pl>). In subgroup analysis, we evaluated the effect of *COMT* Val108/158Met polymorphism on the susceptibility of *BC* in different population stratified by ethnicity (Caucasian, Asian, and Mixed/other), menopausal status (Pre-, and Post-) and sources of the control population (HB, PB, and FB).

For each genetic comparison, a chi-square-based *Q*-statistic test was used to evaluate the between-study heterogeneity of the studies. If *P* \< 0.10, the between-study heterogeneity was considered to be significant, we chose the random-effects model to calculate the OR. Otherwise, when *P* ≥ 0.10, the between study heterogeneity was not significant, then the fixed effects model was used. We also measured the effect of heterogeneity using a quantitative measure, *I*^*2*^ = 100% × (*Q* -- *df*)/*Q*\[[@B19]\]. The *I* statistic measures the degree of inconsistency in the studies by calculating what percentage of the total variation across studies is due to heterogeneity rather than by chance \[[@B20]\]. Finally, the overall or pooled estimate of risk (OR) was calculated by a random effects model (DerSimonian--Laird) or a fixed effects model (Mantel--Haenszel) according to the presence (*P* \< 0.10 or *I*^*2*^ \> 50%) or absence (*P* ≥ 0.10 and *I*^*2*^ ≤ 50%) of heterogeneity, respectively.

Cumulative meta-analysis was conducted to identify the influence of the first published study on the subsequent publications, and the evolution of the combined estimates over time according to the ascending date of publication. To identify potentially influential studies, sensitivity analysis was also performed by excluding the studies without definite diagnostic criteria, the studies without quality control when genotyping and the studies whose genotype frequencies in control populations exhibited significant deviation from the Hardy--Weinberg equilibrium (HWE), given that the deviation may denote bias. The funnel plots and Egger regression asymmetry test were used to assess publication bias. Egger's test can detect funnel plot asymmetry by determining whether the intercept deviates significantly from zero in a regression of the standardized effect estimates against their precision. A T test was performed to determine the significance of the asymmetry. An asymmetric plot suggested possible publication bias (*P* ≥ 0.05 suggests no bias). All analyses were performed using Stata software, version 10.0 (Stata Corp., College Station, TX, USA).

Results
=======

Study characteristics
---------------------

According to our search criteria, 61 studies relevant to the role of *COMT* Val158Met polymorphism on *BC* risk were identified. Ten of these articles were excluded: one of these articles was a review \[[@B21]\], four were overlapped subjects \[[@B22]-[@B25]\], four did not provide allele or genotyping data \[[@B26]-[@B29]\], and one was a study concerned with *COMT* 1222 G\>A polymorphism \[[@B30]\]. Manual search of references cited in the published studies did not reveal any additional articles. As a result, a total of 51 relevant studies met the inclusion criteria for the meta-analysis \[[@B9]-[@B16],[@B31]-[@B73]\]. Among them, five of the eligible studies contained data on two different ethnic groups, and we treated them independently \[[@B31],[@B51],[@B56],[@B60],[@B69]\]. Therefore, a total of 56 separate comparisons consisting of 34,358 *BC* patients and 45,429 controls were included in our meta-analysis. The characteristics of the 56 case--control comparisons selected for determining the relationship between *COMT* Val108/158Met polymorphism and risk of *BC* are summarized in Table  [1](#T1){ref-type="table"}. These 56 comparisons were consisted of 33 Caucasian samples, 18 Asian populations and 5 mixed/other populations. Thirty of the studies were population-based case--control studies and 20 were hospital-based studies, four of these studies \[[@B44],[@B54],[@B60],[@B69]\] presented *COMT* Val158Met polymorphism genotype distributions according to family history (familial-based breast cancer). There were 22 comparisons concerned with *COMT* Val158Met polymorphism and premenopausal BC patients and 27 comparisons concerned with *COMT* Val158Met polymorphism and postmenopausal BC patients (see Table  [1](#T1){ref-type="table"}). Seventy-one percent (40/56) studies in the present meta-analysis used the golden criteria of "histologically confirmed" or "pathologically conformed" as *BC* diagnosis. Eighty-two (46/56) percent of the control populations matched to *BC* patients with age and 52% (29/56) studies used the classic PCR-RFLP assay to genotype the *COMT* Val158Met polymorphism, about 52% (29/56) of the case--control studies included mentioned the quality control when genotyping. The genotype frequencies of control group in 3 studies were not consistent with HWE \[[@B33],[@B41],[@B70]\]. We could not calculate the *P* value of HWE in two studies \[[@B66],[@B73]\] because they only provided data with dominant model. To remove possible HWE stratification, for each analysis involving any of these 5 studies, sensitivity analysis would be carried out by excluding the studies the genotype frequencies for control group of which deviate from HWE and the studies whose *P* value of HWE in the control group could not be calculated.

###### 

**General characteristics of individual studies in the meta-analysis of*COMT*Val158Met polymorphism and breast cancer**

  **Study, year**    **Country**   **Ethnicity**   **No. of cases/controls**   **BC diagnosis**                **Matching criteria**   **Genotyping method**   **Menopausal status**   **Control sources**   **Quality control**   **HWE**^**6**^**(*p*value)**
  ------------------ ------------- --------------- --------------------------- ------------------------------- ----------------------- ----------------------- ----------------------- --------------------- --------------------- ------------------------------
  Lavigne 1997       America       Caucasian       113/114                     NR                              Age, race               PCR-RFLP                Pre-, Post-             HB                    NR                    0.862
  Thompson 1998      America       Caucasian       281/289                     Histologically confirmed        Age, region             PCR-RFLP                Pre-, Post-             PB                    NR                    0.522
  Millikan^a^ 1998   America       Caucasian       389/379                     Histologically confirmed        Age, race               PCR-RFLP                Pre-, Post-             PB                    Yes                   0.916
  Millikan^b^ 1998   America       Mixed/other     265/263                     Histologically confirmed        Age, race               PCR-RFLP                Pre-, Post-             PB                    Yes                   0.838
  Huang 1999         China         Asian           118/125                     Pathologically conformed        NR                      PCR-RFLP                Pre-, Post-             HB                    NR                    0.612
  Goodman 2001       America       Caucasian       112/113                     Histologically confirmed        Age, race               PCR-RFLP                Mixed                   PB                    Yes                   0.788
  Mitrunen 2001      Finland       Caucasian       481/480                     Histologically confirmed        NR                      PCR-RFLP                Pre-, Post-             PB                    NR                    0.921
  Yim 2001           Korea         Asian           163/163                     Histopathologically confirmed   Age                     PCR-RFLP                Pre-, Post-             HB                    Yes                   **0.004**
  Jungestrom 2001    Sweden        Caucasian       126/117                     NR                              Age                     PCR-RFLP                Pre-                    HB                    NR                    0.209
  Hamajima 2001      Japan         Asian           150/165                     Histologically confirmed        NR                      PCR-RFLP                Pre-, Post-             HB                    NR                    0.079
  Kocabas 2002       Turkey        Caucasian       84/103                      Histologically confirmed        Age                     PCR-RFLP                Pre-, Post-             HB                    NR                    0.227
  Comings 2003       America       Caucasian       67/145                      NR                              Region                  PCR-RFLP                Post-                   PB                    NR                    0.335
  Wedren 2003        Sweden        Caucasian       1490/1340                   NR                              Age                     DASH                    Post-                   PB                    Yes                   0.772
  Wu 2003            America       Asian           589/562                     NR                              Age, race               TaqMan                  Mixed                   PB                    NR                    0.646
  Tan 2003           China         Asian           250/250                     Histopathologically confirmed   Age                     PCR-RFLP                Pre-, Post-             HB                    NR                    0.174
  Sazci 2004         Turkey        Caucasian       130/224                     Histopathologically confirmed   Age                     PCR-RFLP                Pre-                    PB                    NR                    **0.000**
  Dunning 2004       UK            Caucasian       2850/1908                   NR                              Age, region             TaqMan                  Post-                   PB                    Yes                   0.232
  Hefler 2004        Austria       Caucasian       391/1698                    Histologically confirmed        Age, region             Sequencing              Mixed                   HB                    Yes                   0.577
  Ahsan 2004         America       Caucasian       313/262                     Histopathologically confirmed   Age                     LP                      Mixed                   FB                    Yes                   0.108
  Modugno 2005       America       Caucasian       250/3950                    Histopathologically confirmed   NR                      TaqMan                  Post-                   PB                    NR                    0.391
  Lin 2005           China         Asian           99/366                      Pathologically conformed        Age, region             PCR-RFLP                Mixed                   PB                    Yes                   0.972
  Lin 2005           China         Asian           87/341                      Pathologically conformed        Age, region             PCR-RFLP                Mixed                   PB                    Yes                   0.393
  Marchand 2005      America       Mixed/other     1339/1370                   NR                              Age                     PCR-RFLP                Post-                   PB                    NR                    0.109
  Wen 2005           China         Asian           1120/1191                   Pathologically conformed        Age                     PCR-RFLP                Pre-, post-             PB                    Yes                   0.698
  Cheng 2005         China         Asian           496/740                     Pathologically conformed        Age                     NR                      Mixed                   HB                    Yes                   0.006
  Gaudet^a^ 2006     America       Caucasian       1048/1092                   Pathologically conformed        Age                     MALDI-TOF               Pre-, post-             PB                    Yes                   0.853
  Gaudet^b^ 2006     Poland        Caucasian       1983/2279                   Histopathologically confirmed   Age                     TaqMan                  Mixed                   PB                    Yes                   0.525
  Gallicchio 2006    America       Caucasian       81/1251                     Pathologically conformed        NR                      TaqMan                  Mixed                   PB                    NR                    0.440
  Chang 2006         China         Asian           189/321                     Histologically confirmed        Age                     PCR-RFLP                Mixed                   HB                    NR                    0.068
  Onay 2006          Canada        Caucasian       398/372                     Pathologically conformed        Age                     TaqMan                  Pre-                    FB                    Yes                   0.283
  Pharoah 2007       UK            Caucasian       2176/2012                   NR                              NR                      TaqMan                  Mixed                   PB                    NR                    0.287
  Ralph^a^ 2007      America       Caucasian       1626/3286                   NR                              Age                     TaqMan                  Pre-, post-             HB                    Yes                   0.758
  Ralph^b^ 2007      America       Caucasian       500/1005                    NR                              Age                     TaqMan                  Pre-, post-             HB                    Yes                   0.549
  Akisik 2007        Turkey        Caucasian       114/108                     NR                              Age                     PCR-RFLP                Mixed                   NR                    NR                    0.966
  Hu 2007            China         Asian           112/110                     Pathologically conformed        Age                     Sequencing              Pre-, post-             HB                    NR                    0.252
  Takata 2007        America       Mixed/other     325/250                     Mammographically examed         Age                     PCR-RFLP                Pre-, post-             PB                    NR                    0.104
  Onay^a^ 2008       Canada        Caucasian       1217/714                    Pathologically conformed        Age                     TaqMan                  Mixed                   FB                    Yes                   0.832
  Onay^b^ 2008       Finland       Caucasian       708/549                     Pathologically conformed        Age                     TaqMan                  Mixed                   FB                    Yes                   0.676
  Justenhoven 2008   Germany       Caucasian       606/622                     NR                              Age                     MALDI-TOF MS            Mixed                   PB                    Yes                   0.654
  He 2009            America       Caucasian       1212/1683                   Pathologically conformed        Age                     TaqMan                  Mixed                   HB                    Yes                   0.850
  Reding 2009        America       Caucasian       891/878                     NR                              Age                     TaqMan                  post-                   PB                    Yes                   0.606
  GENICA 2009        Germany       Caucasian       3144/5481                   Histologically conformed        Age, region             MALDI-TOF MS            post-                   PB                    Yes                   0.094
  Yadav 2009         India         Asian           154/166                     NR                              Region                  PCR-RFLP                Pre-, post-             HB                    NR                    0.570
  Shrubsole 2009     China         Asian           1093/1169                   Pathologically conformed        Age                     PCR-RFLP                Pre-, post-             PB                    Yes                   ---
  Sangrajrang 2009   Thailand      Asian           565/486                     Histologically conformed        NR                      TaqMan                  Mixed                   HB                    Yes                   0.610
  Mónica 2010        Mexico        Caucasian       91/94                       Pathologically conformed        Age, education          PCR-RFLP                Pre-, post-             HB                    NR                    0.669
  Syamala^a^ 2010    India         Asian           219/367                     Histologically conformed        Age                     PCR-RFLP                Mixed                   PB                    NR                    0.183
  Syamala^b^ 2010    India         Asian           140/367                     Histologically conformed        Age                     PCR-RFLP                Mixed                   FB                    NR                    0.183
  Peterson 2010      America       Caucasian       1584/1416                   Pathologically conformed        Age                     TaqMan                  Mixed                   PB                    Yes                   **0.026**
  Delort 2010        France        Caucasian       910/1000                    Pathologically conformed        Age                     TaqMan                  Mixed                   PB                    Yes                   0.230
  Wang 2011          China         Asian           400/400                     Histopathologically conformed   Age                     Sequencing              Pre-, post-             PB                    Yes                   0.389
  Naushad 2011       India         Asian           212/233                     Histopathologically conformed   NR                      PCR-RFLP                Mixed                   HB                    NR                    0.201
  Cribb 2011         Canada        Caucasian       207/621                     Histopathologically conformed   Age                     PCR-RFLP                Mixed                   HB                    NR                    0.208
  Cerne 2011         Slovenia      Caucasian       530/270                     NR                              Age                     TaqMan                  post-                   HB                    Yes                   0.903
  Lajin 2011         Syria         Mixed/other     135/107                     Pathologically conformed        Age                     PCR-RFLP                Pre-, post-             PB                    NR                    0.887
  Santos 2011        Brazil        Mixed/other     62/62                       Pathologically conformed        Age                     PCR-RFLP                Pre-, post-             PB                    NR                    ---

*PB* Population-based *FB* family-based, *HB* hospital-based, *HWE* Hardy--Weinberg equilibrium, *NR* not reported, *Pre-* premenopausal, *Post-* postmenopausal, *PCR-RFLP* PCR-based restriction fragment length polymorphism, *MALDI-TOF MS* matrix assisted laser desorption/ionization time-of-flight mass spectrometry, *LP* Luorescence polarization.

^a,\ b^ They were two different case--control studies in one publication.

Quantitative synthesis of data
------------------------------

The pooled ORs along with their 95% CIs and the results of the heterogeneity test are presented in detail in Table  [2](#T2){ref-type="table"}. Overall, no significant associations between *COMT* Val158Met polymorphism and breast cancer susceptibility were observed in all genetic models when all the eligible studies were pooled into the meta-analysis. No significant associations were found for LL versus HH (OR = 0.999, 95% CI 0.0.925--1.078; *I*^*2*^*=*55.0 and *P* = 0.000 for heterogeneity), HL versus HH (OR = 1.005, 95% CI 0.959--1.052; *I*^*2*^*=*27.1 and *P* = 0.038 for heterogeneity), LL versus HL (OR = 0.983, 95% CI 0.926--1.045; *I*^*2*^*=*44.4 and *P* = 0.000 for heterogeneity), recessive model LL versus HL+HH (OR = 0.988, 95% CI 0.929--1.050; *I*^*2*^*=*51.3 and *P* = 0.000 for heterogeneity) and dominant model LL+HL versus HH (OR = 1.001, 95% CI 0.954--1.051; *I*^*2*^*=*41.0 and *P* = 0.001 for heterogeneity). Next, the effect of *COMT* Val158Met polymorphism on breast cancer risk was evaluated according to ethnicity, menopausal status (Figure  [1](#F1){ref-type="fig"}; Figure  [2](#F2){ref-type="fig"}) and sources of controls. Similarly, no significant association was found in any of the genetic models. We further conducted a meta-analysis after the five studies \[[@B33],[@B41],[@B66],[@B70],[@B73]\] whose genotype frequencies significantly deviated from HWE or whose *P* values of HWE in the control population unable to be calculated were excluded. The results were not materially changed in any genetic models. Sensitivity analysis by excluding the studies without definite diagnostic criteria and the studies without quality control when genotyping did not alter the pattern of the results. Cumulative meta-analysis was performed for dominant model LL +LH versus HH in the overall populations. In the overall populations, the random effects odds ratio was always insignificantly larger or smaller than 1. It changed little from around 0.998 after the year 2007 (Figure  [3](#F3){ref-type="fig"}), indicating the stability of the association.

###### 

**Meta-analysis of the*COMT*Val158Met polymorphism on*BC*susceptibility**

  **Comparison**   **Population**   **Sample size**   **No. of studies**   **Test of association**   **Mode**   **Test of heterogeneity**                                
  ---------------- ---------------- ----------------- -------------------- ------------------------- ---------- --------------------------- ------- --- -------- ------- ------
  LL vs. HH        Overall          17,223            23,069               54                        0.999      0.925-1.078                 0.976   R   117.76   0.000   55.0
                   Caucasian        12,942            18,066               32                        0.960      0.897-1.028                 0.240   R   49.28    0.020   37.1
                   Asian            3,009             3,790                17                        1.243      0.942-1.641                 0.125   R   54.34    0.000   70.6
                   Pre-             2,095             2,523                21                        1.049      0.825-1.334                 0.697   R   48.22    0.000   58.5
                   Post-            7,215             10,138               26                        0.982      0.875-1.102                 0.757   R   45.40    0.008   44.9
                   PB               17,223            23,069               28                        0.999      0.925-1.078                 0.381   R   48.00    0.008   43.7
                   HB               3,800             6,169                20                        1.151      0.946-1.402                 0.160   R   58.86    0.000   67.7
                   FB               1,351             1,140                5                         0.848      0.712-1.010                 0.064   F   4.43     0.351   9.7
  HL vs. HH        Overall          22,589            33,568               54                        1.005      0.959-1.052                 0.845   R   72.70    0.038   27.1
                   Caucasian        19,059            25,912               32                        0.999      0.958-1.042                 0.968   F   30.14    0.510   0.0
                   Asian            4,525             5,781                17                        1.052      0.923-1.200                 0.448   R   36.85    0.002   56.6
                   Pre-             3,204             3,877                21                        0.962      0.871-1.062                 0.440   F   27.59    0.119   27.5
                   Post-            10,480            14,476               26                        1.009      0.954-1.067                 0.762   F   33.83    0.112   26.1
                   PB               17,648            22,679               28                        0.987      0.945-1.030                 0.547   F   3.60     0.463   0.0
                   HB               5,751             9,128                20                        1.075      0.966-1.195                 0.187   R   33.89    0.019   43.9
                   FB               2,102             1,674                5                         0.950      0.824-1.094                 0.476   F   30.98    0.272   12.9
  LL vs. HL        Overall          23,594            31,759               54                        0.983      0.926-1.045                 0.586   R   95.26    0.000   44.4
                   Caucasian        19,579            27,208               32                        0.954      0.911-1.001                 0.055   F   36.02    0.245   13.9
                   Asian            2,538             3,135                17                        1.170      0.895-1.528                 0.251   R   49.83    0.000   67.9
                   Pre-             2,507             3,200                21                        1.060      0.851-1.320                 0.606   R   49.32    0.000   59.4
                   Post-            10,243            14,548               26                        0.969      0.915-1.025                 0.271   F   32.47    0.271   23.0
                   PB               16,437            21,768               28                        0.969      0.909-1.032                 0.324   R   39.76    0.054   32.1
                   HB               4,973             8,203                20                        1.060      0.902-1.245                 0.478   R   48.71    0.000   61.0
                   FB               2,099             1,714                5                         0.882      0.769-1.012                 0.073   F   4.37     0.358   8.6
  LL vs. HL+HH     Overall          34,358            45,429               56                        0.988      0.929-1.050                 0.702   R   108.88   0.000   51.3
                   Caucasian        25,790            35,593               32                        0.956      0.909-1.006                 0.081   R   43.54    0.067   28.8
                   Asian            5,770             7,552                17                        1.204      0.927-1.564                 0.164   R   52.91    0.000   69.8
                   Pre-             3,903             4.800                21                        1.053      0.855-1.297                 0.627   R   49.44    0.000   59.5
                   Post-            13,969            19,581               26                        0.980      0.901-1.065                 0.629   R   37.85    0.048   33.9
                   PB               24,205            31,307               30                        0.966      0.906-1.030                 0.290   R   45.36    0.015   40.5
                   HB               7,262             11,750               20                        1.098      0.934-1.289                 0.257   R   54.38    0.000   65.1
                   FB               2,776             2,264                5                         0.877      0.760-1.013                 0.074   F   4.62     0.328   13.5
  LL+HL vs. HH     Overall          34,358            45,429               56                        1.001      0.954-1.051                 0.953   R   93.20    0.001   41.0
                   Caucasian        25,790            35,593               32                        0.982      0.944-1.022                 0.369   F   37.71    0.189   17.8
                   Asian            5,770             7,552                17                        1.072      0.952-1.208                 0.253   R   42.65    0.001   60.1
                   Pre-             3,933             4.839                22                        1.016      0.890-1.160                 0.815   R   33.81    0.038   37.9
                   Post-            14,001            19,604               27                        1.001      0.924-1.084                 0.987   R   40.17    0.038   35.3
                   PB               24,205            31,307               30                        0.975      0.924-1.028                 0.343   R   42.89    0.047   32.4
                   HB               7,262             11,750               20                        1.091      0.978-1.216                 0.118   R   39.26    0.004   51.6
                   FB               2,776             2,264                5                         0.914      0.799-1.044                 0.186   F   3.81     0.432   0.0

*OR* odds ratio, *CI* confidence intervals, *R* random effects model, *F* fixed effects model, *PB* Population-based study, *HB* Hospital-based study, *FB* Familial-based study, *Pre-* Premenopausal, *Post-* Postmenopausal.

![**OR and 95% CI of individual studies and pooled data for the association between the*COMT*Val158Met polymorphism and*BC*in premenopausal populations using a random-effect model (dominant model LL+HL vs. HH).**](1746-1596-7-136-1){#F1}

![**OR and 95% CI of individual studies and pooled data for the association between the*COMT*Val158Met polymorphism and*BC*in postmenopausal populations using a random-effect model (dominant model LL+HL vs. HH).**](1746-1596-7-136-2){#F2}

![**Cumulative meta-analysis of the association between*COMT*Val158Met polymorphism and breast cancer susceptibility risk of the overall populations using a random effects model (dominant model LL+HL versus HH).** Each study was used as an information step. The vertical dotted line is the summary odds ratio. Bars, 95% confidence interval (CI).](1746-1596-7-136-3){#F3}

Publication bias
----------------

Begg's funnel plots and Egger's tests were performed to assess publication bias. The shapes of the funnel plots revealed no obvious asymmetry (Figure  [4](#F4){ref-type="fig"}). The Egger's test was then used to statistically assess funnel plot symmetry. The results suggested no evidence of publication bias (*t* = 0.94 and *P* = 0.352 for dominant model). The results indicated that the results of these meta-analyses are relatively stable and that publication bias is unlikely to affect the results of the meta-analyses.

![**Funnel plots for publication bias in the studies of the meta-analysis on the association between*COMT*Val158Met polymorphism and breast cancer risk of the overall populations (dominant LL+HL versus HH).**](1746-1596-7-136-4){#F4}

Discussion
==========

Estrogens, estrone, and estradiol are catabolized to catechol estrogens. Estrogen metabolites, such as 4-hydroxyestrone and 4-hydroxyestrone, shown to be involved in breast carcinogenesis \[[@B74]\]. Catechol-O-methyltransferase (*COMT*) catalyzes the O-methylation of these carcinogenic estrogens to methoxyes tradiols and methoxyestrones. In the *COMT* gene, a G to A transition results in an amino acid change (Val/Met) at codon 108 of soluble *COMT* and codon 158 of membrane-bound *COMT*. This amino acid change is believed to result in a 3--4-fold decrease in enzymatic activity \[[@B6],[@B7]\]. It has been hypothesized that individuals who inherit the low activity COMT gene may be at increased risk for breast cancer because of an increased accumulation of the catechol estrogen intermediates. The potential association between the *COMT* Val108/158Met polymorphism and the risk of subsequent *BC* has evoked a huge interest from clinicians, scientists, and the public. During the past few years a large number of studies with case--control design have been carried out to investigate this topic but consistent results have not been reported. We therefore conducted a meta-analysis of the evidence obtained from all published studies in order to elucidate and provide a quantitative reassessment of the association. To our knowledge, this is the most comprehensive meta-analysis to date to evaluate the association between *COMT* Val108/158Met polymorphism and breast cancer risk.

We did not observe a positive relationship between *COMT* Val108/158Met polymorphism and breast cancer risk either overall or among subgroups of women defined by ethnicity, menopausal status or sources of the control population. In previous studies, overall the findings were inconsistent. Lavigne et al. observed a large increase in the risk of breast cancer among postmenopausal obese women carrying the *COMT*-LL genotype, and an inverse association among premenopausal women with the relative risk (RR) for *COMT*-LL stronger among postmenopausal women with high BMI \[[@B9]\]. Thompson et al. reported positive associations for the *COMT*-HL and *COMT*-LL genotypes among premenopausal women and found that modification of RRs by BMI was highest among premenopausal women with a high BMI \[[@B10]\]. A comprehensive study of the entire estrogen-metabolizing pathway (*CYP17, CYP1A1, COMT*) also reported that breast cancer is only associated with the low activity COMT genotype in women with a high BMI and that the *COMT*-LL genotype was strongly associated with breast cancer risk, with an adjusted OR of as high as 4.02 \[[@B12]\]. In contrast to the other studies but in line with the findings of the current study, Lajin et al. did not observe any association between one or two copies of the *COMT*-L allele and breast cancer risk, and did not find strong modification of RR estimates by menopausal status \[[@B72]\]. In an effort to shed some light on the impact of *COMT* Val108/158Met polymorphism on breast cancer risk, two previous meta-analyses \[[@B17],[@B18]\] were conducted almost at the same time to explore the relationship between *COMT* Val108/158Met polymorphism and breast cancer. Ding et al. \[[@B18]\] examined the effect of *COMT* Val158Met polymorphism on breast cancer risk by combining results in meta-analysis. They concluded that *COMT* Val158Met polymorphism was significantly associated with increased breast cancer risk in European population. However, Mao et al. \[[@B17]\] did not find any relationship between *COMT* Val158Met polymorphism and breast cancer risk in any genetic models including among Caucasian, Asian, premenopausal, and postmenopausal women in their meta-analysis, which was consistent with the findings of our study. The discrepancy in previously reported findings was most probably because that the previous studies with relatively small sample size may have insufficient statistical power to detect the exact effect or may have generated a fluctuated risk estimate. However, in our study, large number of cases and controls were pooled from all published studies, which greatly increased statistical power of the analysis and provided enough evidence for us to draw a safe and reliable conclusion.

Heterogeneity is a potential problem that may affect the interpretation of the results. The present meta-analysis showed that there was large heterogeneity between studies (table  [2](#T2){ref-type="table"}). Common reasons for heterogeneity may include differences in the studied populations (e.g., ethnicity, menopausal status), or in methods (e.g., genotyping), or in sample selection (e.g., source of control populations), or it may be due to interaction with other risk factors (e.g., *BRCA* variants). Finding of the source of heterogeneity is one of the most important goals of a meta-analysis. Therefore, we stratified the studies according to ethnicity, source of control subjects of the studies, and menopausal status. Subsequent subgroup analysis stratified by ethnicity, source of control subjects, and menopausal status identified large heterogeneity as well, indicating that menopausal status, ethnicity or source of control subjects contributed little to the existence of overall heterogeneity. Unfortunately, our study had insufficient information for subgroup analysis to detect whether the variants in *BRCA* gene might be great sources of heterogeneity. We found that in three studies \[[@B33],[@B41],[@B70]\] the genotypic frequencies showed significant deviation from the expected frequencies based on Hardy--Weinberg equilibrium and two studies \[[@B66],[@B73]\] provide insufficient data for calculating P value of HWE in the control populations. Excluding these five studies did not alter the heterogeneity between studies. However, when heterogeneity between the studies exists, the results could be interpreted in the context of cumulative meta-analysis, which provides a measure of how much the genetic effect changes as more data accumulate over time \[[@B75]\]. In our study, the results of cumulative meta-analysis for dominant model LL+HL versus HH showed stability in pooled odds ratio after the year 2007 in the overall populations, which provide evidence for drawing safe conclusion about the insignificant association between *COMT* Val158Met polymorphism and breast cancer risk.

Some limitations of this meta-analysis should be acknowledged. First, some studies found significant associations between *COMT* Val108/158Met polymorphism and breast cancer risk in several subgroups of populations, such as associations among postmenopausal women with a low body mass index (BMI) \[[@B10],[@B11]\], a high BMI \[[@B9]\] or women at young ages \[[@B11]\]. It is difficult for a meta-anlysis to derive such specific associations because the results from previous studies were not presented in a uniform standard. Second, our results were based on unadjusted estimates and a more precise analysis should be carried out if individual data were available, this would allow for adjustment by other covariates including age, BMI, ethnicity, lifestyle, and environmental factors. Third, all of the studies were performed in Asian and Caucasian populations. Further studies are needed in other ethnic populations because of possible ethnic differences of the *COMT* polymorphisms. In spite of these, our present meta-analysis also had some advantages. First, substantial number of cases and controls were pooled from all publications concerned with *COMT* Val158Met polymorphism and BC risk, which greatly increased statistical power of the analysis and provided enough evidence for us to draw a safe conclusion. Second, the quality of case--control studies included in this meta-analysis was satisfactory according to our selection criteria. Third, no publication bias was detected in this meta-analysis, which indicated that the pooled results of our study should be reliable.

In conclusion, this meta-analysis suggests that the *COMT* Val158Met polymorphism may not be associated with breast cancer risk. However, it is necessary to conduct large sample studies using standardized unbiased genotyping methods, homogeneous breast cancer patients, and well-matched controls. Moreover, gene-gene and gene-environment interactions should also be considered in the analysis. Such studies taking these factors into account may eventually lead to a better, more comprehensive understanding of the association between *COMT* Val158Met polymorphism and BC risk.
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